[Intraperitoneal cisplatin in peritoneal carcinomatosis patients].
Cisplatin (100 mg) was given by intraperitoneal infusion to 23 patients with peritoneal carcinomatosis. Eighteen patients had gastric cancer, and five had colorectal cancer. The effects of this therapy were as follows. 1) In gastric cancer patients, the mean survival period was 11.0 months. The cumulative survival rate was superior at the level of statistical significance in comparison with controls. 2) The side effects of this agent given intraperitoneally were mild. In particular, nausea was slightly less than with intravesicular or intraarterial infusion.
D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010529:Peritoneal Cavity; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000401:mortality; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality
D002945:Cisplatin